Scarica l'app Stockscreener
1.11
3.74%
0.04
Dopo l'orario di chiusura:
1.11
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Immunic Inc Borsa (IMUX) Ultime notizie
Immunic's IMU-856 shows potential in gastrointestinal health trialsICYMI - Proactive Investors UK
Immunic, Inc. (NASDAQ:IMUX) Short Interest Update - MarketBeat
Avidity Partners Management LP's Strategic Acquisition in Immuni - GuruFocus.com
Richard Rudick Spends US$100k On Immunic Stock - Simply Wall St
Insider Buys Additional US$100k In Immunic Stock - Yahoo Finance
Janus Henderson Group PLC's Strategic Reduction in Immunic Inc H - GuruFocus.com
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
RTW INVESTMENTS, LP Acquires Additional Shares in Immunic Inc - GuruFocus.com
Immunic announces publication of IMU-856 data - Yahoo Finance
Director Richard Rudick Acquires 87,300 Shares of Immunic Inc (I - GuruFocus.com
Immunic director Richard Rudick buys $100,368 in stock By Investing.com - Investing.com Australia
Immunic director Richard Rudick buys $100,368 in stock - Investing.com
Immunic announces publication of IMU-856 Phase 1 trial data in peer-reviewed journal - Proactive Investors UK
Immunic reports positive Phase 1 results for celiac disease therapy published in The Lancet - Proactive Investors USA
Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology - PR Newswire
Immunic, Inc. (NASDAQ:IMUX) Q3 2024 Earnings Call Transcript - Insider Monkey
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges By GuruFocus - Investing.com Canada
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic P - GuruFocus.com
Immunic Inc (IMUX) Q3 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges - Yahoo Finance
Immunic Reports Q3 Earnings and Provides Corporate Update - TipRanks
Immunic, Inc. Advances MS Trials Amid Financial Update - TipRanks
Immunic, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Immunic: Q3 Earnings Snapshot - Milford Mirror
Immunic Inc (IMUX) Quarterly 10-Q Report - Quartzy
Immunic Reports Third Quarter 2024 Financial Results and Provides Corporate Update - citybiz
Immunic highlights progress in multiple sclerosis programs, targets 2025 milestones - Proactive Investors USA
Immunic CEO details progress following productive third quarter - Proactive Investors UK
Immunic's Phase 3 MS Trial Advances Despite Wider Q3 Loss; $59.1M Cash Runway | IMUX Stock News - StockTitan
Immunic's Jessica Breu talks BIO-Europe & MS research advancements - Proactive Investors USA
Vanguard Group's Strategic Acquisition of Immunic Inc Shares - GuruFocus.com
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - Quantisnow
Immunic (IMUX) Set to Announce Quarterly Earnings on Thursday - MarketBeat
EQS-News: Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Updateboerse.de - boerse.de
Immunic to Participate in Industry, Scientific and Investor Conferences in November - StockTitan
Brokerages Set Immunic, Inc. (NASDAQ:IMUX) PT at $11.20 - MarketBeat
Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 29.5% in October - MarketBeat
Reviewing Immunic (NASDAQ:IMUX) & Acasti Pharma (NASDAQ:ACST) - Defense World
We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate - Simply Wall St
Immunic Therapeutics CMO Dr. Andreas Muehler on Positive Interim Analysis for RMS Trials - Proactive Investors Australia
Immunic late-stage program for lead asset to proceed as planned - MSN
Data monitoring committee OKs continuation of phase 3 trial for vidofludimus calcium - Healio
Interim analysis allows Immunic to stick with phase III MS studies - BioWorld Online
Immunic stock slips after trial update (IMUX:NASDAQ) - Seeking Alpha
Immunic Phase 3 MS study advances following positive recommendation from independent committee - Proactive Investors Australia
Immunic Shares Up 12% on Positive MS Drug Analysis - MarketWatch
Immunic's phase 3 ENSURE trials for MS drug proceed as planned - Investing.com
Immunic, Inc. Announces Positive Outcome of Interim Analysis of Phase 3 Ensure Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis - Marketscreener.com
EQS-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosisboerse.de - boerse.de
Immunic Stock Set to Rise with Consistent Buy Ratings from Analysts - Nasdaq
0.93%
3.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):